Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400506 | 0.83 | IP6K1 (0.53) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL8327914 | 0.81 | MAOA (0.61) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL3899573 | 0.80 | IP6K1 (0.56) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL26355932 | 0.80 | IP6K1 (0.56) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL30530239 | 0.80 | IP6K1 (0.56) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL1486580 | 0.80 | IP6K1 (0.56) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL14117442 | 0.80 | MAOB (0.56) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL30530243 | 0.80 | MAOB (0.61) | IP6K1CYP3A4MAOAMAOBNPC1 | |
| SCHEMBL30530234 | 0.80 | LMNA (0.64) | IP6K1CYP3A4MAOBPLAUPLAT | |
| SCHEMBL26355934 | 0.80 | MAOB (0.61) | IP6K1CYP3A4MAOAMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2247584-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009093049-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053935-A1 | FUSED PYRIDINES ACTIVE AS INHIBITORS OF C-MET | MET, ROS1, ABL1 | IP6K1 1530/4885CYP3A4 371/4885MAOA 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.